X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (751) 751
Book Review (267) 267
Publication (61) 61
Transcript (8) 8
Newspaper Article (7) 7
Book Chapter (3) 3
Magazine Article (3) 3
Conference Proceeding (2) 2
Dissertation (1) 1
Newsletter (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (536) 536
oncology (493) 493
humans (487) 487
chemotherapy (388) 388
cancer (316) 316
female (302) 302
maintenance therapy (250) 250
lung neoplasms - drug therapy (216) 216
middle aged (211) 211
male (210) 210
aged (208) 208
carcinoma, non-small-cell lung - drug therapy (197) 197
antineoplastic combined chemotherapy protocols - therapeutic use (180) 180
care and treatment (167) 167
maintenance (165) 165
gemcitabine (156) 156
adult (154) 154
lung cancer (152) 152
lung cancer, non-small cell (150) 150
treatment outcome (150) 150
bevacizumab (136) 136
phase-iii trial (134) 134
carboplatin (129) 129
double-blind (129) 129
lung neoplasms - pathology (122) 122
cisplatin (121) 121
open-label (121) 121
disease-free survival (117) 117
cancer therapies (115) 115
research (115) 115
antineoplastic agents - therapeutic use (114) 114
carcinoma, non-small-cell lung - pathology (109) 109
erlotinib (104) 104
survival (103) 103
pemetrexed (102) 102
maintenance chemotherapy (101) 101
ovarian cancer (101) 101
hematology, oncology and palliative medicine (100) 100
non-small cell lung cancer (100) 100
neoplasm staging (99) 99
analysis (93) 93
metastasis (93) 93
therapy (93) 93
trial (91) 91
clinical trials (90) 90
patients (88) 88
aged, 80 and over (82) 82
medicine & public health (82) 82
lung neoplasms - mortality (81) 81
mutation (81) 81
supportive care (79) 79
paclitaxel (77) 77
carcinoma, non-small-cell lung - mortality (76) 76
drug therapy (76) 76
pharmacology & pharmacy (72) 72
antineoplastic agents (71) 71
respiratory system (70) 70
1st-line treatment (68) 68
antimitotic agents (67) 67
tumors (67) 67
multicenter (66) 66
health aspects (65) 65
survival rate (63) 63
review (62) 62
antineoplastic combined chemotherapy protocols - adverse effects (61) 61
docetaxel (61) 61
immunotherapy (61) 61
animals (59) 59
deoxycytidine - analogs & derivatives (59) 59
ovarian neoplasms - drug therapy (58) 58
placebo (58) 58
quality of life (58) 58
olaparib maintenance therapy (57) 57
prognosis (55) 55
nsclc (54) 54
cell lung-cancer (53) 53
non-small-cell lung cancer (53) 53
breast cancer (52) 52
oncology, experimental (52) 52
retrospective studies (52) 52
survival analysis (51) 51
phase-ii trial (50) 50
phase-iii (50) 50
hematology (49) 49
maintenance bevacizumab (49) 49
cisplatin - administration & dosage (48) 48
medical research (48) 48
pancreatic cancer (48) 48
cancer research (47) 47
development and progression (47) 47
gefitinib (47) 47
neoplasms. tumors. oncology. including cancer and carcinogens (47) 47
studies (47) 47
disease progression (46) 46
randomized phase-iii (46) 46
guanine - analogs & derivatives (45) 45
toxicity (44) 44
1st-line chemotherapy (43) 43
adenocarcinoma (43) 43
deoxycytidine - administration & dosage (43) 43
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
International Journal of Radiation Oncology, Biology, Physics, ISSN 0360-3016, 2012, Volume 84, Issue 5, pp. 1166 - 1171
Purpose Local failure in unresectable pancreatic cancer may contribute to death. We hypothesized that intensification of local therapy would improve local... 
Radiology | Hematology, Oncology and Palliative Medicine | RATE INFUSION | THERAPY | RADIOSENSITIZATION | ONCOLOGY | ADENOCARCINOMA | I TRIAL | MAINTENANCE GEMCITABINE | RADIOTHERAPY | CARCINOMA | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | Organs at Risk - radiation effects | Adenocarcinoma - pathology | Humans | Middle Aged | Gastrointestinal Tract - radiation effects | Male | Cause of Death | Radiotherapy, Intensity-Modulated - adverse effects | Neutropenia - etiology | Radiation-Sensitizing Agents - administration & dosage | Time Factors | Aged, 80 and over | Deoxycytidine - adverse effects | Dose Fractionation | Female | Pancreatic Neoplasms - mortality | Adenocarcinoma - radiotherapy | Deoxycytidine - administration & dosage | Pancreatic Neoplasms - pathology | Radiotherapy, Intensity-Modulated - methods | Pancreatic Neoplasms - radiotherapy | Thrombocytopenia - chemically induced | Radiation-Sensitizing Agents - adverse effects | Disease Progression | Maximum Tolerated Dose | Aged | Deoxycytidine - analogs & derivatives | Adenocarcinoma - mortality | Cancer patients | Care and treatment | Gemcitabine | Nuclear radiation | Pancreatic cancer | Clinical trials | Product development | Cancer | Index Medicus | Adenocarcinoma | PATIENTS | VOMITING | FAILURES | PERFORMANCE | PANCREAS | NEUTROPHILS | DEATH | RADIATION DOSES | TOXICITY | BILIRUBIN | ALANINES | DEHYDRATION | CARCINOMAS | CREATININE | NAUSEA | RADIOLOGY AND NUCLEAR MEDICINE | DOSE RATES | ANOREXIA | FEVER | PERFORATION | chemoradiotherapy | pancreatic cancer | gemcitabine | IMRT | local control
Journal Article
Annals of Oncology, ISSN 0923-7534, 9/2008, Volume 19, Issue 9, pp. 1592 - 1599
Background: The role of chemoradiation with systemic chemotherapy compared with chemotherapy alone in locally advanced pancreatic cancer (LAPC) is uncertain.... 
5-fluorouracil | Gemcitabine | Pancreatic cancer | Maintenance | Overall survival | Chemoradiotherapy | Randomized phase III trial | Cisplatin | CONSOLIDATIVE CHEMORADIATION | ADENOCARCINOMA | chemoradiotherapy | INITIAL TREATMENT | RANDOMIZED-TRIAL | CHEMOTHERAPY | RADIATION-THERAPY | pancreatic cancer | COMBINED RADIOCHEMOTHERAPY | ONCOLOGY | randomized phase III trial | overall survival | gemcitabine | RADIOTHERAPY | cisplatin | maintenance | CONCURRENT CHEMORADIOTHERAPY | Immunohistochemistry | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Follow-Up Studies | Humans | Middle Aged | Male | Cisplatin - administration & dosage | Dose-Response Relationship, Drug | Fluorouracil - administration & dosage | Fluorouracil - adverse effects | Neoplasm Invasiveness - pathology | Adult | Deoxycytidine - adverse effects | Female | Pancreatic Neoplasms - mortality | Chemotherapy, Adjuvant | Radiotherapy, Adjuvant | Radiotherapy Dosage | Drug Administration Schedule | Risk Assessment | Deoxycytidine - administration & dosage | Pancreatic Neoplasms - pathology | Probability | Treatment Outcome | Combined Modality Therapy | Remission Induction | Survival Analysis | Cisplatin - adverse effects | Aged | Biopsy, Needle | Infusions, Intravenous | Neoplasm Staging | Deoxycytidine - analogs & derivatives | Pancreatic Neoplasms - therapy | Index Medicus
Journal Article
BMC Cancer, ISSN 1471-2407, 12/2014, Volume 14, Issue 1, pp. 953 - 953
Journal Article
Lung Cancer, ISSN 0169-5002, 2006, Volume 52, Issue 2, pp. 155 - 163
The primary objective of this randomized phase III study was to show significant difference in median time to progression (TTP) in patients with advanced NSCLC... 
Phase III | Best supportive care | Maintenance | Gemcitabine | Cisplatin | Non-small cell lung cancer | non-small cell lung cancer | SURVIVAL | MULTICENTER | CARBOPLATIN | best supportive care | phase III | RANDOMIZED-TRIAL | COMBINATION | ETOPOSIDE | THERAPY | ONCOLOGY | RESPIRATORY SYSTEM | gemcitabine | QUALITY-OF-LIFE | cisplatin | maintenance | DURATION | PLUS | Lung Neoplasms - drug therapy | Injections, Intravenous | Follow-Up Studies | Lung Neoplasms - mortality | Humans | Immunosuppressive Agents - therapeutic use | Middle Aged | Lung Neoplasms - pathology | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Cisplatin - administration & dosage | Deoxycytidine - therapeutic use | Adult | Female | Retrospective Studies | Drug Therapy, Combination | Immunosuppressive Agents - administration & dosage | Carcinoma, Non-Small-Cell Lung - pathology | Deoxycytidine - administration & dosage | Survival Rate | Treatment Outcome | Carcinoma, Non-Small-Cell Lung - mortality | Cisplatin - therapeutic use | Ribonucleotide Reductases - antagonists & inhibitors | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Deoxycytidine - analogs & derivatives | Medical colleges | Chemotherapy | Lung diseases | Clinical trials | Product development | Lung cancer, Non-small cell | Cancer | Index Medicus
Journal Article
International Journal of Radiation Oncology, Biology, Physics, ISSN 0360-3016, 2011, Volume 81, Issue 4, pp. e615 - e622
Purpose Stereotactic body radiotherapy (SBRT) has been used successfully to treat patients with locally advanced pancreas cancer. However, many patients... 
Radiology | Hematology, Oncology and Palliative Medicine | Chemotherapy | Stereotactic body radiotherapy | Gemcitabine | Locally advanced pancreatic cancer | CONSOLIDATIVE CHEMORADIATION | ADENOCARCINOMA | RADIATION-THERAPY | PHASE-III TRIAL | 5-FLUOROURACIL | ONCOLOGY | MAINTENANCE GEMCITABINE | CARCINOMA | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | CONCURRENT | COOPERATIVE-ONCOLOGY-GROUP | Radiotherapy Planning, Computer-Assisted - methods | Humans | Middle Aged | Male | Radiosurgery - adverse effects | Neoplasm Staging - methods | Pancreatic Neoplasms - drug therapy | Radiation-Sensitizing Agents - therapeutic use | Deoxycytidine - therapeutic use | Aged, 80 and over | Adult | Female | Pancreatic Neoplasms - mortality | Retrospective Studies | CA-19-9 Antigen - blood | Radiosurgery - methods | Radiotherapy Dosage | Drug Administration Schedule | Pancreatic Neoplasms - pathology | Pancreatic Neoplasms - surgery | Induction Chemotherapy - methods | Combined Modality Therapy - adverse effects | Aged | Combined Modality Therapy - methods | Deoxycytidine - analogs & derivatives | Medical colleges | Pancreatic cancer | Analysis | Metastasis | Radiotherapy | Cancer | Index Medicus | DIAGNOSIS | PATIENTS | NEOPLASMS | METASTASES | PANCREAS | RADIOLOGY AND NUCLEAR MEDICINE | RADIATION DOSES | TOXICITY | RADIOTHERAPY | CHEMOTHERAPY
Journal Article
The Journal of biological chemistry, ISSN 0021-9258, 02/2019, Volume 294, Issue 6, pp. 1763 - 1778
Journal Article
Journal Article
Journal of geriatric oncology, 08/2019
OBJECTIVESThe aim of this study was to evaluate the efficacy and safety of the combination Gemcitabine (Gem) plus nab-Paclitaxel (NabP) (Gem/NabP), followed by... 
Index Medicus
Journal Article
BMC Research Notes, ISSN 1756-0500, 2013, Volume 6, Issue 1, pp. 3 - 3
Journal Article
Cancer, ISSN 0008-543X, 06/2011, Volume 117, Issue 12, pp. 2620 - 2628
BACKGROUND: The purpose of this study was to assess the efficacy and safety of 5-fluorouracil (5FU) and gemcitabine administered concurrently with radiation in... 
combined modality therapy | pancreatic cancer | gemcitabine | 5‐fluorouracil | radiation | 5-fluorouracil | CONSOLIDATIVE CHEMORADIATION | MITOMYCIN-C | CANCER | GROWTH-FACTOR RECEPTOR | ONCOLOGY | I TRIAL | MAINTENANCE GEMCITABINE | FULL-DOSE GEMCITABINE | CONCURRENT CHEMORADIOTHERAPY | III TRIAL | COOPERATIVE-ONCOLOGY-GROUP
Journal Article
Gynecologic Oncology, ISSN 0090-8258, 03/2018, Volume 148, Issue 3, pp. 507 - 514
Determine the maximum tolerated dose (MTD) and recommended phase II dose (RP2D) of veliparib combined with carboplatin and gemcitabine in patients with... 
Phase I | BRCA1/2 mutations | Veliparib | PARP inhibitor | Ovarian cancer | INTERGROUP TRIAL | FALLOPIAN-TUBE | BRCA 1/2 mutations | CHEMOTHERAPY | OBSTETRICS & GYNECOLOGY | CELL LUNG-CANCER | BREAST-CANCER | RIBOSYLATION | GERMLINE BRCA1 | ONCOLOGY | ABT-888 | RECURRENT EPITHELIAL OVARIAN | PRIMARY PERITONEAL | Lung Neoplasms - drug therapy | Skin Neoplasms - drug therapy | Nausea - chemically induced | Area Under Curve | Humans | Middle Aged | Ovarian Neoplasms - pathology | Induction Chemotherapy | Male | Ovarian Neoplasms - genetics | Neoplasm Metastasis | Carcinoma, Hepatocellular - drug therapy | Benzimidazoles - administration & dosage | Aged, 80 and over | Genes, BRCA2 | Germ-Line Mutation | Adult | Female | Maintenance Chemotherapy | Genes, BRCA1 | Neutropenia - chemically induced | Ovarian Neoplasms - drug therapy | Prostatic Neoplasms - drug therapy | Bile Duct Neoplasms - drug therapy | Deoxycytidine - administration & dosage | Liver Neoplasms - drug therapy | Anemia - chemically induced | Carboplatin - administration & dosage | Treatment Outcome | Thrombocytopenia - chemically induced | Breast Neoplasms - drug therapy | Mesothelioma - drug therapy | Poly(ADP-ribose) Polymerase Inhibitors - administration & dosage | Kidney Pelvis | Maximum Tolerated Dose | Breast Neoplasms - genetics | Carcinoma, Squamous Cell - drug therapy | Gallbladder Neoplasms - drug therapy | Cholangiocarcinoma - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Bayes Theorem | Carcinoma, Transitional Cell - drug therapy | Carcinoma, Basal Cell - drug therapy | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Kidney Neoplasms - drug therapy | Deoxycytidine - analogs & derivatives | Index Medicus
Journal Article